| Literature DB >> 32244977 |
Joan J Castellano1,2, Ramon M Marrades2,3, Laureano Molins2,4, Nuria Viñolas2,5, Jorge Moises2,3, Jordi Canals1,2, Bing Han1,2, Yan Li1,2, Daniel Martinez2,6, Mariano Monzó1,2, Alfons Navarro1,2.
Abstract
Hypoxia-induced upregulation of lincRNA-p21 in tumor tissue was previously shown by our group to be related to poor prognosis in resected non-small cell lung cancer (NSCLC) patients. In the present study, we have evaluated the presence of lincRNA-p21 in extracellular vesicles (EVs) from NSCLC patients and assessed its potential as a prognostic biomarker. High EV lincRNA-p21 levels in blood from the tumor-draining vein were associated with shorter time to relapse and shorter overall survival. Moreover, the multivariate analysis identified high lincRNA-p21 levels as an independent prognostic marker. In addition, lincRNA-p21 was overexpressed in H23 and HCC44 NSCLC cell lines and their derived EVs under hypoxic conditions. Functional assays using human umbilical vein endothelial cells (HUVECs) showed that tumor-derived EVs enriched in lincRNA-p21 affected endothelial cells by promoting tube formation and enhancing tumor cell adhesion to endothelial cells. Additionally, the analysis of selected EV microRNAs related to angiogenesis and metastasis showed that the microRNAs correlated with EV lincRNA-p21 levels in both patients and cell lines. Finally, EV co-culture with HUVEC cells increased the expression of microRNAs and genes related to endothelial cell activation. In conclusion, EV lincRNA-p21 acts as a novel prognosis marker in resected NSCLC patients, promoting angiogenesis and metastasis.Entities:
Keywords: NSCLC; angiogenesis; exosomes; extracellular vesicles; lincRNA-p21; lncRNAs; tumor-draining vein
Year: 2020 PMID： 32244977 DOI： 10.3390/cancers12030734
Source DB: PubMed Journal: Cancers (Basel) ISSN： 2072-6694 Impact factor: 6.639